Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Allogene Therapeutics, Inc.ALLO · Entity 5243 | Director | June 18, 2026 | June 23, 2026 |
| CITIGROUP INCC · Entity 2837 | Director | April 01, 2019 | April 02, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Allogene Therapeutics, Inc.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 95,400 |
Reported balance
After 2026-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 95,400 · Balance 95,400 F1: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Company Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. The reporting person has elected to defer the receipt of Common Stock upon the vesting of their RSUs pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i) 30 days following separation from continuous service with the company and (ii) a change in control of the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Company Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. The reporting person has elected to defer the receipt of Common Stock upon the vesting of their RSUs pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i) 30 days following separation from continuous service with the company and (ii) a change in control of the Company.
CITIGROUP INC
Report date April 01, 2019 · Filed April 02, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 21,304.0024 |
Reported balance
After 2019-04-01 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2019-04-01 · Grant · Acquired 151.3481 · Balance 21,304.0024 F1: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. F2: Represents deferred shares of common stock held by the Issuer for the benefit of the Reporting Person pursuant to the Issuer's Compensation Plan for Non-Employee Directors. |
| Common StockSEC Table I · non-derivative | Direct | 2,668.8124 |
Reported balance
After 2019-04-01 transaction · row 2
1 source rowRow 2 · 2019-04-01 · Grant · Acquired 14.6923 · Balance 2,668.8124 F1: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors.
F2: Represents deferred shares of common stock held by the Issuer for the benefit of the Reporting Person pursuant to the Issuer's Compensation Plan for Non-Employee Directors.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Kite Pharma, Inc.
Report date October 03, 2017 · Filed October 05, 2017
Section 16 reporting ended · disclosed 2017-10-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2017-10-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-10-03 · Other · Disposed 4,624 · Balance 1,807 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F2: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. Row 2 · 2017-10-03 · Disposition to issuer · Disposed 1,807 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F2: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F3: Represents shares of Company common stock underlying restricted stock units with respect to Company common stock, including all time-vesting and all performance-vesting restricted stock units, held by a non-employee director of the Company (each a "Director Restricted Stock Unit"). Pursuant to the terms of the Merger Agreement, each Director Restricted Stock Unit held by the Reporting Person fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of (A) $180.00, multiplied by (B) the total number of shares of Company common stock subject to such Director Restricted Stock Unit. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.12 · Expires 2025-09-08 | Direct | 0 |
Reported balance
After 2017-10-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-10-03 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F2: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F5: This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option. F4: This option provided for vesting in 36 equal monthly installments commencing October 9, 2015. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.87 · Expires 2026-05-31 | Direct | 0 |
Reported balance
After 2017-10-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-10-03 · Disposition to issuer · Disposed 7,000 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F2: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F5: This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option. F6: This option provided for vesting in 12 equal monthly installments following June 1, 2016. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $91.21 · Expires 2027-06-19 | Direct | 0 |
Reported balance
After 2017-10-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-10-03 · Disposition to issuer · Disposed 8,810 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes. F2: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F5: This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option. F7: This option provided for vesting in 12 equal monthly installments following June 20, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes.
F2: On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the "Merger"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes.
F3: Represents shares of Company common stock underlying restricted stock units with respect to Company common stock, including all time-vesting and all performance-vesting restricted stock units, held by a non-employee director of the Company (each a "Director Restricted Stock Unit"). Pursuant to the terms of the Merger Agreement, each Director Restricted Stock Unit held by the Reporting Person fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of (A) $180.00, multiplied by (B) the total number of shares of Company common stock subject to such Director Restricted Stock Unit.
F4: This option provided for vesting in 36 equal monthly installments commencing October 9, 2015.
F5: This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option.
F6: This option provided for vesting in 12 equal monthly installments following June 1, 2016.
F7: This option provided for vesting in 12 equal monthly installments following June 20, 2017.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 16, 2016 Filed Feb 18, 2016 22:18 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 4,048.5 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-100024 · doc4.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,022.8 F1 · shares: Deferred shares awarded under the Issuer's Compensation Plan for Non-Employee Directors. F2 · balance_after: Reflects 3,031.7 shares of deferred common stock which vested on 1/20/2016 and were transferred to the Reporting Person's deferred compensation account in accordance with the terms of the Issuer's Compensation Plan for Non-Employee Directors. Read SEC document |
| January 01, 2016 Filed Jan 5, 2016 22:20 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 7.1 | $53.31 | $378.49 |
DisclosureSEC source: 0001209191-16-089019 · doc4.xml · nonDerivative · entry 2 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,636.7 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. F2 · balance_after: Represents deferred shares of common stock held by the Issuer for the benefit of the Reporting Person pursuant to the Issuer's Compensation Plan for Non-Employee Directors. Read SEC document |
| January 01, 2016 Filed Jan 5, 2016 22:20 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 5.6 | $53.31 | $298.52 |
DisclosureSEC source: 0001209191-16-089019 · doc4.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,006 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. Read SEC document |
| October 01, 2015 Filed Oct 5, 2015 20:08 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 7.4 | $51.28 | $379.44 |
DisclosureSEC source: 0001209191-15-073804 · doc4.xml · nonDerivative · entry 2 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,629.6 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. F2 · balance_after: Represents deferred shares of common stock held by the Issuer for the benefit of the Reporting Person pursuant to the Issuer's Compensation Plan for Non-Employee Directors. Read SEC document |
| October 01, 2015 Filed Oct 5, 2015 20:08 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 5.8 | $51.28 | $297.40 |
DisclosureSEC source: 0001209191-15-073804 · doc4.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000.4 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. Read SEC document |
| July 01, 2015 Filed Jul 6, 2015 20:01 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 5.3 | $55.94 | $296.46 |
DisclosureSEC source: 0001181431-15-008691 · rrd425854.xml · nonDerivative · entry 2 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,994.6 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. Read SEC document |
| July 01, 2015 Filed Jul 6, 2015 20:01 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 6.8 | $55.94 | $380.36 |
DisclosureSEC source: 0001181431-15-008691 · rrd425854.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,622.2 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. F2 · balance_after: Represents deferred shares of common stock held by the Issuer for the benefit of the Reporting Person pursuant to the Issuer's Compensation Plan for Non-Employee Directors. Read SEC document |
| April 01, 2015 Filed Apr 3, 2015 18:01 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 0.5686 | $53.16 | $30.23 |
DisclosureSEC source: 0001181431-15-005550 · rrd423700.xml · nonDerivative · entry 2 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,989.3 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. Read SEC document |
| April 01, 2015 Filed Apr 3, 2015 18:01 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 1.4 | $53.16 | $74.43 |
DisclosureSEC source: 0001181431-15-005550 · rrd423700.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,615.4 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. F2 · balance_after: Represents deferred shares of common stock held by the Issuer for the benefit of the Reporting Person pursuant to the Issuer's Compensation Plan for Non-Employee Directors. Read SEC document |
| February 18, 2015 Filed Feb 20, 2015 13:12 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 2,966.1 | $0.00 | $0.00 |
DisclosureSEC source: 0001181431-15-002881 · rrd422300.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,988.8 F1 · shares: Deferred shares awarded under the Issuer's Compensation Plan for Non-Employee Directors. F2 · balance_after: Reflects 3,419 shares of deferred common stock which vested on 1/20/2015 and were transferred to the Reporting Person's deferred compensation account in accordance with the terms of the Issuer's Compensation Plan for Non-Employee Directors. Read SEC document |
| January 01, 2015 Filed Jan 5, 2015 21:05 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 0.7642 | $54.88 | $41.94 |
DisclosureSEC source: 0001181431-15-000240 · rrd419869.xml · nonDerivative · entry 2 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,194.9 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. F2 · balance_after: Represents deferred shares of common stock held by the Issuer for the benefit of the Reporting Person pursuant to the Issuer's Compensation Plan for Non-Employee Directors. Read SEC document |
| January 01, 2015 Filed Jan 5, 2015 21:05 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 1.1 | $54.88 | $60.37 |
DisclosureSEC source: 0001181431-15-000240 · rrd419869.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,441.5 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. Read SEC document |
| October 01, 2014 Filed Oct 3, 2014 20:02 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 0.8048 | $52.10 | $41.93 |
DisclosureSEC source: 0001181431-14-033512 · rrd416423.xml · nonDerivative · entry 2 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,194.2 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. F2 · balance_after: Represents deferred shares of common stock held by the Issuer for the benefit of the Reporting Person pursuant to the Issuer's Compensation Plan for Non-Employee Directors. Read SEC document |
| October 01, 2014 Filed Oct 3, 2014 20:02 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 1.2 | $52.10 | $62.52 |
DisclosureSEC source: 0001181431-14-033512 · rrd416423.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,440.5 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. Read SEC document |
| July 01, 2014 Filed Jul 3, 2014 18:05 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 0.8646 | $48.50 | $41.93 |
DisclosureSEC source: 0001181431-14-026168 · rrd411554.xml · nonDerivative · entry 2 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,193.4 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. F2 · balance_after: Reflects 4,192.5892 shares of deferred common stock which vested on 7/1/2014 and were transferred to the Reporting Person's deferred compensation account in accordance with the terms of the Issuer's Compensation Plan for Non-Employee Directors. Read SEC document |
| July 01, 2014 Filed Jul 3, 2014 18:05 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 1.3 | $48.50 | $63.05 |
DisclosureSEC source: 0001181431-14-026168 · rrd411554.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,439.3 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. F2 · balance_after: Reflects 4,192.5892 shares of deferred common stock which vested on 7/1/2014 and were transferred to the Reporting Person's deferred compensation account in accordance with the terms of the Issuer's Compensation Plan for Non-Employee Directors. Read SEC document |
| April 01, 2014 Filed Apr 3, 2014 20:05 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 2.1 | $48.54 | $101.93 |
DisclosureSEC source: 0001181431-14-015383 · rrd405930.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,630.4 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. Read SEC document |
| February 18, 2014 Filed Feb 20, 2014 22:06 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 3,020.2 | $0.00 | $0.00 |
DisclosureSEC source: 0001181431-14-008031 · rrd401803.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,628.3 F1 · shares: Deferred shares awarded under the Issuer's Compensation Plan for Non-Employee Directors. Read SEC document |
| January 01, 2014 Filed Jan 3, 2014 21:03 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 1.4 | $51.58 | $72.21 |
DisclosureSEC source: 0001181431-14-000751 · rrd397258.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,608.1 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. Read SEC document |
| October 01, 2013 Filed Oct 3, 2013 19:11 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 1.5 | $50.17 | $75.26 |
DisclosureSEC source: 0001181431-13-052268 · rrd390861.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,606.4 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. Read SEC document |
| July 01, 2013 Filed Jul 3, 2013 20:43 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 1.5 | $50.65 | $75.97 |
DisclosureSEC source: 0001181431-13-038705 · rrd383376.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,604.9 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. Read SEC document |
| July 01, 2013 Filed Jul 3, 2013 20:44 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 1.5 | $50.65 | $75.97 |
DisclosureSEC source: 0001181431-13-038710 · rrd383376.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,604.9 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. Read SEC document |
| July 01, 2013 Filed Jul 3, 2013 20:42 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 1.5 | $50.65 | $75.97 |
DisclosureSEC source: 0001181431-13-038723 · rrd383376.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,604.9 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. Read SEC document |
| April 01, 2013 Filed Apr 3, 2013 20:09 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 0.9227 | $45.39 | $41.88 |
DisclosureSEC source: 0001181431-13-020520 · rrd373337.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,603.4 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. Read SEC document |
| February 19, 2013 Filed Feb 21, 2013 22:34 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 3,414.3 | $0.00 | $0.00 |
DisclosureSEC source: 0001181431-13-011431 · rrd368130.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,602.5 F1 · shares: Deferred shares awarded under the Issuer's Compensation Plan for Non-Employee Directors. Read SEC document |
| January 01, 2013 Filed Jan 3, 2013 21:11 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 1.1 | $36.62 | $40.28 |
DisclosureSEC source: 0001181431-13-000966 · rrd364823.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,188.2 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. Read SEC document |
| October 01, 2012 Filed Oct 3, 2012 20:08 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 1.2 | $32.35 | $38.82 |
DisclosureSEC source: 0001181431-12-053297 · rrd356546.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,187.1 F1 · shares: Reinvestment of cash, including dividends and interest, under the Compensation Plan for Non-Employee Directors. Read SEC document |
| July 01, 2012 Filed Jul 3, 2012 18:44 UTC | CITIGROUP INC C · Entity 2837 | GrantCommon Stock | 4,185.8 | $0.00 | $0.00 |
DisclosureSEC source: 0001181431-12-039304 · rrd349220.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,185.8 F1 · shares: Deferred shares awarded under the Issuer's Compensation Plan for Non-Employee Directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.